Compare AZTR & MLEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AZTR | MLEC |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.9M |
| IPO Year | 2023 | N/A |
| Metric | AZTR | MLEC |
|---|---|---|
| Price | $0.35 | $0.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 308.2K | 131.3K |
| Earning Date | 11-12-2025 | 01-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.42 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 170.36 |
| 52 Week Low | $0.30 | $0.39 |
| 52 Week High | $4.33 | $8.00 |
| Indicator | AZTR | MLEC |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 36.36 |
| Support Level | $0.34 | $0.41 |
| Resistance Level | $0.39 | $0.48 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 46.47 | 24.66 |
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.